Clinical trials: Brest Cancer
Brest Cancer ER+ and HER2 Negative
De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer
This study is a randomized, open-label, phase II trial designed to evaluate whether alternate-day dosing of letrozole preserves antiproliferative activity compared with standard daily dosing in postmenopausal women with estrogen…
- Trial name
- DELTA (NCT07866430)
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Montefiore Medical Center
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Breast Cancer
Construction of an Ultrasound Profile and a Mammographic Profile Corresponding to the Different Molecular Subtypes of Brest Cancer. A Retrospective Study
PROFILS is a retrospective, exploratory study on data collected in 203 breast cancer cases diagnosed during a national screening campaign from 2015 to 2018.
- Trial name
- PROFILS (NCT05757232)
- Volunteers
- 203 people
- Sponsor
- Elsan
Brest Cancer, CDK4/6 Inhibitor
Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients
This study aims to evaluate the efficacy and safety of branded palbociclib (Ibrance®) compared to available local generic formulations (Palbociclib-IPI) in Iraqi patients with hormone receptor-positive, human epidermal growth…
- Trial name
- PALLAS-IRAQ (NCT07493291)
- Testing
- Palbociclib (Brand vs Generic) compartive
- Where
- Iraq
- Volunteers
- 100 people
- Sponsor
- Al-Mustansiriyah University
Brest Cancer, Abemaciclib
Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)
Overall survival at 8 years under treatment for localized hormone-dependent breast cancer is 93.3% (1). Adjuvant therapy, especially hormone therapy, helps reduce the risk of recurrence.
- Conditions
- Brest Cancer, Abemaciclib, Adjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols
- Trial name
- MONARCHE29 (NCT06621459)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Brest
Brest Cancer
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
This study aims to explore the efficacy and safety of neratinib combined with fulvestrant and eribulin in the treatment of HR+/HER2+ advanced breast cancer after trastuzumab deruxtecan resistance.
- Trial name
- NETHER (NCT07333937)
- Testing
- Neratinib Combined with Fulvestrant and Eribulin
- Volunteers
- 35 people
- Sponsor
- Xijing Hospital
Polycythemia Vera, Essential Thrombocythemia
Myeloproliferative Neoplastic Diseases Observatory From Brest
All patients diagnosed or followed in Brest University Hospital for Philadelphia negative myeloproliferative neoplasms will be included in this observational study.
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis
- Trial name
- OBENE (NCT02897297)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Brest
Programmed Cell Death 1
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer
Surgery is first-line treatment for solid tumors. However, surgical trauma-induced physiologic stress has been demonstrated to facilitate metastasis and recurrence in different types of cancer.
- Trial name
- NCT04657237
- Testing
- Thoracic Paravertebral block
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Assiut University
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Brest Cancer
Creation and Implementation a Method for Breast Reconstruction After Radical Surgery Using Decellularized Xenomatrix in Combination With Lymphovenous Anastomosis in Breast Cancer.
In 2020, more than 31,000 new cancer cases were reported in Kazakhstan, with breast cancer being the most common type, accounting for more than 4,200 new cases.
- Trial name
- NCT07782801
- Testing
- Radical mastectomy with axillary lymph node dissection, Immediate implant-based breast reconstruction, Acellular xenogeneic matrix (AXM)
- Where
- Kazakhstan
- Volunteers
- 60 people
- Sponsor
- National Research Oncology and Transplantology Center, Kazakhstan
Modified Radical Mastectomy, Drain Effect
Active Drainage vs. Passive Drainage in MRM
The aim of the study is to compare between active drainage and passive drainage in post-operative seroma formation after modified radical mastectomy in female patient with breast carcinoma as regard of: Primary Outcomes: 1.
- Conditions
- Modified Radical Mastectomy, Drain Effect, Seroma Formation, Brest Cancer
- Trial name
- MRM Drains (NCT07621575)
- Testing
- compare active and passive drain
- Where
- Egypt
- Volunteers
- 157 people
- Sponsor
- MOHAMED GAMAL AHMED ARAKEEB
Brest Cancer
Thyroid Dysfunction Induced by Radiotherapy Treatment in Patients with Breast Cancer
Breast cancer is the most common cancer and second most common cause of cancer death among US women,. External beam radiation therapy (RT) that involves the breast and regional lymph nodes, including axillary and supraclavicular…
- Trial name
- NCT06820554
- Volunteers
- 97 people
- Sponsor
- Assiut University
Breast Neoplasm Female, Surgery
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Current guidelines lack definitive evidences about the relative benefits of locoregional surgery for the primary tumor in de novo stage IV breast cancer.
- Conditions
- Breast Neoplasm Female, Surgery, Advanced Breast Cancer
- Trial name
- SYSBTC-001 (NCT04456855)
- Testing
- Locoregional surgery
- Where
- 3 sites in China
- Volunteers
- 358 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Neoplasms Diagnosis, Brest Cancer
Wide-Angle Tomosynthesis and AI in Diagnostic Mammography
Breast cancer remains the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women globally. Timely and accurate detection is crucial for improving prognosis and survival outcomes.
- Trial name
- NCT07491055
- Volunteers
- 1,400 people
- Sponsor
- Jean Seely
Head and Neck Tumor, Breast Cancer
Topical Diclofenac for Prevention of Radiation-induced Dermatitis
Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy.
- Trial name
- NCT06905561
- Testing
- Diclofenac Sodium Gel
- Where
- China
- Volunteers
- 156 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Meningioma
Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin
Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of…
- Trial name
- MAP (NCT04109404)
- Where
- France
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Breast Cancer Patients
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient
polymorphisms of drug transporter genes may influence of Doxorubicin-Cyclophosphamide toxicity in breast cancer patients. the investigators want to evaluate the association between associations between genetic polymorphisms of…
- Trial name
- NCT04654195
- Testing
- polymorphism analysis, Doxorubicin-Cyclophosphamide regimen
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Damanhour University
Metastatic Breast Cancer
Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)
Nab-paclitaxel has demonstrated to be an active agent in breast cancer and probably a less toxic alternative to solvent based taxanes. It is indicated in metastatic breast cancer after failure of anthracyclines.
- Trial name
- NCT01416558
- Testing
- Nab-Paclitaxel
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- GBG Forschungs GmbH
Metastatic Breast Cancer
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
Target Population: female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy.
- Trial name
- NCT01477060
- Testing
- Lapatinib, Metformin
- Where
- 11 sites in Italy
- Volunteers
- 32 people
- Sponsor
- Fondazione Michelangelo